Following successful experience in the metastatic setting where different EGFR TKIs are currently approved [5,6,7,8,9,10], several studies aimed to demonstrate a survival advantage with the use of these agents as adjuvant therapy in EGFR-mutated resected NSCLC (Table 1). This evidence concerns the gene EGFR and non-small cell lung carcinoma.